Objective: Despite demonstration of the superior outcomes of transcatheter aortic valve implantation (TAVI) versus optimal medical therapy for severe left ventricular systolic dysfunction, studies comparing TAVI and surgical aortic valve replacement (AVR) in this high-risk group have been lacking.Methods: We performed propensity matching for age, gender, baseline comorbidities, previous interventions, priority at hospital admission, frailty score, New York Heart Association class, EuroSCORE, and associated cardiac diseases. Next, the 30-day mortality and procedure-related morbidity of 162 patients (81 TAVI vs 81 AVR) with severe left ventricular systolic dysfunction (ejection fraction <= 35%) were analyzed at the Italian National Institute of Health.Results: The 30-day mortality was comparable (P = .37) between the 2 groups. The incidence of periprocedural acute myocardial infarction (P = .55), low output state (P = .27), stroke (P = .36), and renal dysfunction (peak creatinine level, P.57) was also similar between the 2 groups. TAVI resulted in significantly greater postprocedural permanent pacemaker implantation (P = .01) and AVR in more periprocedural transfusions (P <. 01) despite a similar transfusion rate per patient (2.8 +/- 3.7 for TAVI vs 4.4 +/- 3.8 for AVR; P.08). The postprocedural intensive care unit stay (median, 2 days after TAVI vs 3 days after AVR; P = .34), intermediate care unit stay (median, 0 days after both TAVI and AVR; P = .94), and hospitalization (median, 11 days after TAVI vs 14 days after AVR; P = .51) were comparable.Conclusions: In patients with severe left ventricular systolic dysfunction, both TAVI and AVR are valid treatment options, with comparable hospital mortality and periprocedural morbidity. Comparisons of the mid-to long-term outcomes are mandatory.

Effect of severe left ventricular systolic dysfunction on hospital outcome after transcatheter aortic valve implantation or surgical aortic valve replacement: results from a propensity-matched population of the Italian OBSERVANT multicenter study

Onorati, Francesco;Santini, Francesco;
2014-01-01

Abstract

Objective: Despite demonstration of the superior outcomes of transcatheter aortic valve implantation (TAVI) versus optimal medical therapy for severe left ventricular systolic dysfunction, studies comparing TAVI and surgical aortic valve replacement (AVR) in this high-risk group have been lacking.Methods: We performed propensity matching for age, gender, baseline comorbidities, previous interventions, priority at hospital admission, frailty score, New York Heart Association class, EuroSCORE, and associated cardiac diseases. Next, the 30-day mortality and procedure-related morbidity of 162 patients (81 TAVI vs 81 AVR) with severe left ventricular systolic dysfunction (ejection fraction <= 35%) were analyzed at the Italian National Institute of Health.Results: The 30-day mortality was comparable (P = .37) between the 2 groups. The incidence of periprocedural acute myocardial infarction (P = .55), low output state (P = .27), stroke (P = .36), and renal dysfunction (peak creatinine level, P.57) was also similar between the 2 groups. TAVI resulted in significantly greater postprocedural permanent pacemaker implantation (P = .01) and AVR in more periprocedural transfusions (P <. 01) despite a similar transfusion rate per patient (2.8 +/- 3.7 for TAVI vs 4.4 +/- 3.8 for AVR; P.08). The postprocedural intensive care unit stay (median, 2 days after TAVI vs 3 days after AVR; P = .34), intermediate care unit stay (median, 0 days after both TAVI and AVR; P = .94), and hospitalization (median, 11 days after TAVI vs 14 days after AVR; P = .51) were comparable.Conclusions: In patients with severe left ventricular systolic dysfunction, both TAVI and AVR are valid treatment options, with comparable hospital mortality and periprocedural morbidity. Comparisons of the mid-to long-term outcomes are mandatory.
2014
35
35.2
AMI
AVR
FRANCE-2
French Transcatheter Aortic Valve Intervention
ICU
ImCU
LCOS
LVEF
PARTNER
PPM
Placement of AoRTic TraNscathetER
SAS
SLVSD
TAVI
VARC
Valve Academic Research Consortium
acute myocardial infarction
aortic valve replacement
intensive care unit
intermediate care unit
left ventricular ejection fraction
low cardiac output syndrome
permanent pacemaker
severe aortic stenosis
severe left ventricular systolic dysfunction
transcatheter aortic valve implantation
Age Factors
Aged
Aged, 80 and over
Aortic Valve Stenosis
Blood Transfusion
Comorbidity
Critical Care
Female
Heart Valve Prosthesis Implantation
Hospital Mortality
Humans
Italy
Length of Stay
Logistic Models
Male
Middle Aged
Postoperative Complications
Propensity Score
Prospective Studies
Registries
Risk Assessment
Risk Factors
Severity of Illness Index
Sex Factors
Stroke Volume
Time Factors
Treatment Outcome
Ventricular Dysfunction, Left
Cardiac Catheterization
Ventricular Function, Left
File in questo prodotto:
File Dimensione Formato  
OBSERVANT impact LV dysfunction JTCV2014.pdf

non disponibili

Tipologia: Versione dell'editore
Licenza: Accesso ristretto
Dimensione 163.36 kB
Formato Adobe PDF
163.36 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/1025585
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 24
  • ???jsp.display-item.citation.isi??? 24
social impact